Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of PDR001 in advanced NSCLC with KRAS/NRAS mutation or no actionable genomic alterations
KCT0002975Phase 2Not yet recruiting
- Sponsor
- Asan Medical Center
- Start
- Sep 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of spartalizumab in non-small cell lung cancer (NSCLC), sponsored by Asan Medical Center. Planned start Sep 2018; status: not yet recruiting.
02
Drugs
spartalizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on KCT0002975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0002975.